饲料添加剂

Search documents
东北固收转债分析:金威转债定价:首日转股溢价率33-36%
NORTHEAST SECURITIES· 2025-08-21 08:43
[Table_Info1] 证券研究报告 [Table_Title] 证券研究报告/债券研究报告 金威转债定价:首日转股溢价率 33-36% 报告摘要: ---东北固收转债分析 [Table_Summary] 8 月 18 日,金达威发布公告,拟于 2025 年 8 月 20 日通过网上发行可转 债,公司本次计划发行可转换公司债券募集资金总额不超过 12.92 亿元。 其中 2.97 亿元拟用于投资"辅酶 Q10 改扩建项目",总投资 3.2 亿元; 4.64 亿元拟用于投资"年产 30,000 吨阿洛酮糖、年产 5,000 吨肌醇建设 项目",总投资 5.37 亿元;1.44 亿元拟用于投资"信息化系统建设项目", 总投资 1.53 亿元;3.88 亿元拟用于补充流动资金。 金威转债发行方式为优先配售,网上发行,债项和主体评级 AA。发行规 模为 12.92 亿元,初始转股价格为 19.59 元,参考 8 月 19 日正股收盘价 格 19.58 元,转债平价 99.95 元,参考同期限同评级中债企业债到期收益 率(8 月 18 日)为 2.47%,到期赎回价 110 元,计算纯债价值为 98.2 元。 博弈 ...
北交所消费服务产业跟踪第二十四期:氨基酸市场规模稳步扩张,北交所无锡晶海为氨基酸原料药“小巨人”
Hua Yuan Zheng Quan· 2025-07-29 13:41
Market Overview - The global amino acid market is projected to grow from $26.19 billion in 2021 to $49.42 billion by 2030, with a CAGR of 7.3%[2] - In 2023, China's amino acid market reached ¥43.635 billion, reflecting a year-on-year growth of 4.2%[2] - In 2020, China accounted for 32.23% of the global amino acid market, leading the world[2] Industry Dynamics - China's amino acid production is dominated by glutamic acid (42.06%) and lysine (36.80%) as of 2020[19] - The domestic amino acid industry has a complete supply chain, with applications in animal feed, food additives, pharmaceuticals, and fine chemicals[6] - The demand for high-value-added amino acids is increasing, with products like phenylalanine and isoleucine gaining traction[2] Company Spotlight - Wuxi Jinghai is recognized as a "little giant" in amino acid raw materials, focusing on branched-chain amino acids and other products[26] - In 2024, Wuxi Jinghai's revenue from amino acid raw materials is expected to constitute 57% of its total revenue[30] - The company has obtained a food production license, allowing it to expand its amino acid applications in the food sector[29] Market Performance - From July 21 to July 25, 2025, the median market cap change for North Exchange consumer service stocks was +1.68%, with 70% of companies experiencing an increase[37] - The median P/E ratio for North Exchange consumer service companies decreased from 58.6X to 57.1X during the same period[39] Investment and Expansion - Companies like Baixinglong are establishing subsidiaries in Italy and Hong Kong to enhance their international market presence[56] - The global raw material drug market is expected to reach $226.1 billion in 2024, growing at a rate of 5.3%[27]
欧盟对华氯化胆碱作出反倾销初裁
news flash· 2025-07-08 07:20
Core Points - The European Commission has made a preliminary affirmative anti-dumping ruling on Choline Chloride originating from China, with specific temporary anti-dumping duties imposed on various companies [1] - The investigation period for dumping is set from October 1, 2023, to September 30, 2024, while the damage investigation period spans from January 1, 2021, until the end of the dumping investigation period [1] Company-Specific Summaries - Shandong Aocter Feed Additives Co., Ltd. faces a temporary anti-dumping duty of 120.8% [1] - Shandong FY Feed Technology Co., Ltd. and Shandong Yinfeng Biological Technology Co., Ltd. are both subject to a temporary anti-dumping duty of 95.4% [1] - Other cooperating companies will incur a temporary anti-dumping duty of 99.8%, while other non-cooperating companies will also face a duty of 120.8% [1] Regulatory Process - Interested parties have a timeframe of 5 calendar days from the announcement to submit requests for hearings and 15 calendar days to submit comments on the case [1] - The CN codes for the products involved in this case are specified, indicating the classification for regulatory purposes [1]
安迪苏: 北京市金杜律师事务所关于蓝星安迪苏股份有限公司向特定对象发行A股股票的补充法律意见书
Zheng Quan Zhi Xing· 2025-06-26 16:20
Core Viewpoint - The document outlines the legal opinions and supplementary legal advice provided by King & Wood Mallesons regarding Blue Star Adisseo Co., Ltd.'s issuance of A-shares to specific targets, emphasizing compliance with Chinese laws and regulations [1][2][3]. Group 1: Issuance Details - The issuance includes projects such as a 150,000 tons/year solid methionine project and a 37,000 tons/year specialty feed additive project, among others [4][5]. - The company has not yet obtained the necessary overseas investment filing for the Burgos specialty feed additive project [4][5]. Group 2: Legal Compliance - The law firm confirms that it only provides opinions on Chinese legal matters and does not assess non-legal professional matters such as finance or accounting [3][4]. - The supplementary legal opinion is an integral part of the previously issued legal documents and maintains the same assumptions and premises [2][4]. Group 3: Overseas Investment - The overseas investment project is to be implemented by the company's subsidiary in Spain, focusing on specialty feed additives [7][8]. - The company has submitted the necessary overseas investment filing to the Ministry of Commerce, and there are no significant legal uncertainties expected regarding this process [10][12]. Group 4: Financial Assistance - The company has provided financial assistance to its joint venture, Calysseo, to support the construction of a facility for producing single-cell protein, which is strategically aligned with its core business [15][16]. - The financial assistance provided does not constitute a related party transaction under the Shanghai Stock Exchange rules [17][18].
星湖科技: 关于2024年年度报告的信息披露监管问询函的回复公告
Zheng Quan Zhi Xing· 2025-06-25 16:47
Core Viewpoint - The company, Guangdong Zhaoqing Xinghuo Biotechnology Co., Ltd. (Xinghuo Technology), has received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, particularly focusing on its cash flow from investment activities, which has shown continuous outflows over the past three years [1][2]. Investment Activities - The net cash flow from investment activities for the years 2022 to 2024 was -789 million, -859 million, and -864 million yuan respectively, indicating a consistent cash outflow [1]. - The cash payments for investments during the same period were 1.579 billion, 2.412 billion, and 1.8 billion yuan [1]. Major Investment Projects - The company has detailed its major investment projects, including the acquisition of 99.22% of Ningxia Yipin Biotechnology Co., Ltd. for a total transaction price of 5.376 billion yuan, with 4.585 billion yuan paid through share issuance and 791.6384 million yuan in cash [3][4]. - The decision to use self-owned funds for the cash payment of the acquisition was approved by the board of directors, adhering to the company's investment decision-making procedures [4]. Financial Performance - The company reported operating revenues of 1.601 billion, 1.606 billion, and 1.605 billion yuan for the years 2022 to 2024, with net profits attributable to the parent company of 120.579 million, 75.997 million, and 108.141 million yuan respectively [6]. - The net cash flow from operating activities increased from 211.975 million yuan in 2022 to 239.776 million yuan in 2024, indicating improved operational efficiency [19]. Cash Management and Investment Strategy - As of the end of 2024, the company had a cash balance of 1.759 billion yuan, a year-on-year increase of 23.97%, with interest income of 13 million yuan [9]. - The company has established a risk management system and a comprehensive financial management policy to control investment risks, including a clear approval process for investment products [8]. Debt and Financing - The company’s long-term borrowings stood at 1.721 billion yuan and short-term borrowings at 1.008 billion yuan at the end of 2024, with interest expenses of 110 million yuan [9]. - The company has been reducing its bank loan balance over the years, with a total bank borrowing of 3.391 billion yuan at the end of 2024, down from 4.188 billion yuan in 2022 [19]. Acquisition and Goodwill - The company acquired 100% of Sichuan Jiuling Pharmaceutical Technology Co., Ltd. in 2019, resulting in goodwill of 198 million yuan, which has been subject to impairment testing due to declining profitability in subsequent years [20][23].
美农生物:年产10万吨玉米蛋白精加工项目正在有序推进中
Quan Jing Wang· 2025-05-20 05:27
公开资料显示,美农生物成立于1997年,专业从事饲料添加剂的研发、生产和销售,深耕行业超过27 年,产品广泛应用于猪、反刍、家禽、水产等动物。在提高动物采食量、消化能力,维护动物肠道健 康,促进动物生长,提升奶品质,节约饲料资源等方面发挥重要作用。(全景网) 更多业绩说明会详情,请点击:https://rs.p5w.net/html/146179.shtml 美农生物财务总监周茜回复:公司净利润同比下降,主要受境内市场竞争加剧、对外投资收益下降、补 助类收益下降等因素影响;公司虽然境内业务有所下滑,但境外业务依然保持稳健发展势头。公司坚持 国际化战略,业务已覆盖亚洲、欧洲、非洲、南美洲等40多个国家及地区,境外营收同比增长25%。 2025年公司将继续加大对境外市场的投入,扩大先发优势,推动境外市场业务持续增长。同时,对于境 内市场持续推进产品的研发与创新,不断提升新技术、新产品、新方案,保持领先的产品和技术服务竞 争力。子公司乐陵美农建设的年产10万吨的玉米蛋白精加工项目正在有序推进中,一期工程有望在2025 年建成投产,将促进公司产品结构的优化,为公司拓展新的收入利润增长点。 5月19日,美农生物(301 ...
美农生物(301156) - 上海美农生物科技股份有限公司投资者关系活动记录表20250519
2025-05-19 12:53
Group 1: Company Strategy and Product Development - The company adopts a "segmented species, comprehensive nutrition" product development strategy, establishing a diverse product system to enhance competitive advantages in a challenging market [2][3] - Various comprehensive solutions are provided to meet different customer needs, such as improving animal feed intake and maintaining gut health [3] - The company focuses on continuous product innovation and development, particularly in the fields of feed additives and enzymatic protein feed materials [4][7] Group 2: Market Position and Growth Opportunities - The company has a global market presence, covering various animal categories including pigs, poultry, ruminants, and aquaculture [4] - International market revenue increased by 25% year-on-year, while domestic market revenue has faced challenges for three consecutive years [6][9] - The company plans to expand its product applications in ruminants and aquaculture to mitigate risks associated with the cyclical nature of the pig farming industry [5][9] Group 3: Financial Performance and Management - In Q1 2025, the company reported revenue of 99.85 million, a year-on-year increase of 1.99%, while net profit decreased by 5.4% [6][9] - The company emphasizes cash flow management through inventory optimization and accounts receivable recovery, aiming to enhance operational cash flow [5][9] - R&D investment decreased by 4.93%, but the number of R&D personnel increased by 7.25%, indicating a focus on maintaining technological advantages [8][10] Group 4: Future Outlook and Risk Management - The company acknowledges uncertainties in the market, such as competition and raw material price fluctuations, but views these as both challenges and opportunities [4][9] - The company is committed to enhancing its operational quality and creating sustainable returns for investors through improved communication and engagement [6][9] - The company is advancing a corn protein processing project with an annual capacity of 100,000 tons, expected to be operational by 2025, to optimize product structure and create new revenue streams [9][10]
安迪苏: 安迪苏2024年年度权益分派实施公告
Zheng Quan Zhi Xing· 2025-05-12 10:17
证券代码:600299 证券简称:安迪苏 公告编号:2025-026 蓝星安迪苏股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ? 每股分配比例 A 股每股现金红利0.12元(含税) ? 相关日期 股份类别 股权登记日 最后交易日 除权(息)日 现金红利发放日 A股 2025/5/19 - 2025/5/20 2025/5/20 ? 差异化分红送转: 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 3 月 24 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后,在中国证券登记结算有限责任 公司上海分公司(以下简称"中国结算上海分公司")登记在册的本公司全体股东。 本次利润分配以方案实施前的公司总股本2,681,901,273股为基数,每股派发现 金红利0.12元(含税),共计派发现金红利321,828,152.76元(含税)。 三、 相关日期 股份类别 股权登记日 最后交易日 除权(息)日 现 ...
安迪苏(600299) - 安迪苏2025年一季度主要经营数据公告
2025-04-28 10:04
证券代码:600299 证券简称:安迪苏 公告编号:2025-025 蓝星安迪苏股份有限公司 2025 年一季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 蓝星安迪苏股份有限公司(以下简称"安迪苏"或"公司")根据上海证券交 易所相关行业信息披露指引要求的要求,现将公司 2025 年一季度主要经营数据 披露如下: 一、 主要产品销售情况 营业收入分产品情况 单位:元 币种:人民币 | | | | | 主营业务分产品情况 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 分产品 | 营业收入 | 营业成本 | 毛利率 | 营业收 入比上 | 营业成 本比上 | | 毛利率比上年增减 | | | | | | | | | (%) | | | | | | 年增减 | 年增减 | | | | 功能性产品 | 3,318,731,133 | 2,452,653,060 | 26% | 29% | 32% | 减少 | 2 个百分点 | | 特种产品 ...
全球饲料级维生素 D3(胆钙化醇)市场前5强生产商排名及市场占有率
QYResearch· 2025-04-28 09:30
饲料级维生素 D3(胆钙化醇)全球市场总体规模 据 QYResearch 调研团队最新报告"全球饲料级维生素 D3 (胆钙化醇)市场报告 2025-2031 "显示, 预计 2031 年全球饲料级维生素 D3 (胆钙 化醇)市场规模将达到 0.7 亿美元 ,未来几年年复合增长率 CAGR 为 3.5% 。 全球 饲料级维生素 D3 (胆钙化醇) 市场前 8 强生产商排名及市场占有率(基于 2 02 4 年调研数据;目前最新数据以本公司最新调研 数据为准) 根据 QYResearch 头部企业研究中心调研,全球范围内饲料级维生素 D3 (胆钙化醇)生产商主要包括浙江花园高科、新和成、海盛制药、金达 威、帝斯曼、浙江医药、天新药业、 Fermenta 等。 2024 年,全球前五大厂商占有大约 91.0% 的市场份额。 就产品类型而言,目前维生素 D3 粉是最主要的细分产品,占据大约 77.7% 的份额。 就产品应用而言,目前反刍动物饲料是最主要的需求来源,占据大约 43.8% 的份额。 主要驱动因素: 维生素 D3 对动物正常的钙磷代谢至关重要,而钙磷代谢对骨骼发育、生长和整体健康至关重要。随着全球畜牧业和水产 ...